• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Dynamic Contrast-Enhanced CT Detects More Colorectal Liver Metastasis

Article

The contrast-enhanced CT also improves lesion conspicuity over standard care of monophasic portovenous CT.

Liver model

Dynamic contrast-enhanced CT increased the detection of colorectal liver metastasis, especially for lesions smaller than 15 mm, according to a study published in the European Journal of Radiology.

Researchers from Belgium performed a prospective study to evaluate a dynamic contrast-enhanced CT-protocol and compare this method with standard of care monophasic portovenous CT for detection of colorectal liver metastases.

Related article: Dynamic Contrast-Enhanced, Susceptibility Contrast MR Images Help Grade Gliomas

A total of 135 treatment-naïve patients participated in the study. All underwent dynamic contrast-enhanced CT, followed by routine monophasic portovenous CT of thorax-abdomen-pelvis. Forty-two of the patients presented with liver metastasis. The number and lesion conspicuity of detected liver metastasis on dynamic contrast-enhanced CT using perfusion maps was compared to monophasic CT.

The results showed that dynamic contrast-enhanced CT outperformed portovenous CT for detection as well as conspicuity of colorectal liver metastasis, at a relatively low dose increment.

The researchers concluded that using dynamic contrast-enhanced CT increased the detection of colorectal liver metastasis, especially for lesions smaller than 15 mm, when compared to monophasic portovenous CT. Dynamic contrast-enhanced CT also has the added advantage of improved lesion conspicuity, which can positively influence reader confidence and clinical workflow.

Recent Videos
Radiology Study Finds Increasing Rates of Non-Physician Practitioner Image Interpretation in Office Settings
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Nina Kottler, MD, MS
Practical Insights on CT and MRI Neuroimaging and Reporting for Stroke Patients
Related Content
© 2024 MJH Life Sciences

All rights reserved.